.RESEARCH STUDY HIGHLIGHT.06 August 2024.
A big randomized measured trial with cisgender women highlights the difficulties of faithfulness to a regular oral preexposure treatment program as well as displays that twice-yearly treatment of lenacapavir can easily maintain efficient HIV protection levels over 6 months.